Europe Autoimmune Monoclonal Antibodies Market By Source (Murine, Chimeric, Humanized, & Human), By Application (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Transplant Rejection/Graft Versus Host Disease, & Others), and By End User (Hospitals/Clinics, Research Institutes, & Diagnostic Laboratories) – Market Analysis, Size, Geographic Countries Analysis, Competitive Strategies Analysis and Forecasts (2016 to 2021)

Europe Autoimmune Monoclonal Antibodies Market By Source (Murine, Chimeric, Humanized, & Human), By Application (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Transplant Rejection/Graft Versus Host Disease, & Others), and By End User (Hospitals/Clinics, Research Institutes, & Diagnostic Laboratories) – Market Analysis, Size, Geographic Countries Analysis, Competitive Strategies Analysis and Forecasts (2016 to 2021)

ID: 1172 | Pages: 138 | November 2016 | Region: Europe


Europe Autoimmune Monoclonal Antibodies market is expected to reach USD 8,302.0 million by 2021 from USD 5,718.7 million in 2016, growing at a CAGR of 7.74% during forecast period 2016-2021. Irregular functioning of humans’ immune system results in autoimmune disorders. Overproduction of self-reactive immune cells (such as antibodies & T-cells) damage regular functions of /cells/tissues/organs. This lead to different autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and others diseases. Typically, drugs are used as a treatment to cure autoimmune disorders. The adverse effects associated with drugs has made switched to concentrate on monoclonal antibodies.

Monoclonal antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat autoimmune diseases. Recent years have seen the emergence of monoclonal antibodies being used to treat wide array of diseases that are related to immune response. These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus monoclonal antibodies due to its customizable nature can be used to treat the self-reactive immune cells not impacting the normal ones.

Increasing government initiations, growing technological advancements, presence of developed healthcare infrastructure, and rising demand for advanced therapies are driving the growth of autoimmune monoclonal antibodies market in Europe. However, certain regulatories and improper reimbursement policies are restraining the growth of autoimmune monoclonal antibodies market in Europe.

Europe Autoimmune Monoclonal Antibodies market is segmented based on source, application, and end user. Based on source, the market is further sub-segmented as Murine, Chimeric, Humanized, and Human. Among these, humanized segment is expected to command the largest share in Europe Autoimmune Monoclonal Antibodies market, by source in 2016. Based on application, the market is further segmented as Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Transplant Rejection/Graft Versus Host Disease, and Others. Of these, rheumatoid arthritis application is anticipated to command the major share in Europe Autoimmune Monoclonal Antibodies market, by application in 2016. Based on end user, the market is further segmented as Hospitals/Clinics, Research Institutes, and Diagnostic Laboratories. Among these, Hospitals/Clinics segment is expected to hold the major market share in Europe Autoimmune Monoclonal Antibodies market, by application in 2016.

On the basis of geographical areas, Europe Autoimmune Monoclonal Antibodies market is segmented as U.K., Germany, France, Italy, and Spain.

The key players in Autoimmune Monoclonal Antibodies market include, GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Application                           

                                5.2.1 Systemic Lupus Erythematosus      

                                5.2.2 Rheumatoid Arthritis          

                                5.2.3 Multiple Sclerosis 

                                5.2.4 Transplant Rejection/Graft Versus Host Disease     

                                5.2.5 Others      

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

6. Geographical Analysis                                              

                6.1 Europe                         

                                6.1.1 Introduction           

                                6.1.2 U.K             

                                6.1.3 Spain         

                                6.1.4 Germany 

                                6.1.5 Italy           

                                6.1.6 France      

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 AstraZeneca plc (U.K.)                           

                9.6 Innovent Biologics, Inc. (China)                          

                9.4 Bristol-Myers Squibb (U.S.)                 

                9.5 Johnson & Johnson (U.S.)                    

                9.6 Innovent Biologics, Inc. (China)                          

                9.7 Takeda Pharmaceutical Company Ltd. (Japan)                             

                9.8 Amgen Inc. (U.S.)                     

                9.9 Biogen Inc.(U.S.)                      

                9.10 UCB Company (Belgium)                    

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

TitlePriceAdd To Cart
  1. Europe Autoimmune Monoclonal Antibodies Market By Region, From 2016-2021 ( USD Million )
  2. Europe Autoimmune Monoclonal Antibodies Market By Source, From 2016-2021 ( USD Million )
  3. Europe Murine Monoclonal Antibodies Market By Region, From 2016-2021 ( USD Million )
  4. Europe Chimeric Monoclonal Antibodies Market By Region, From 2016-2021 ( USD Million )
  5. Europe Humanized Monoclonal Antibodies Market By Region, From 2016-2021 ( USD Million )
  6. Europe Human Monoclonal Antibodies Market By Region, From 2016-2021 ( USD Million )
  7. Europe Autoimmune Monoclonal Antibodies Market By Application, From 2016-2021 ( USD Million )
  8. Europe Systemic Lupus Erythematosus Market By Region, From 2016-2021 ( USD Million )
  9. Europe Rheumatoid Arthritis Market By Region, From 2016-2021 ( USD Million )
  10. Europe Multiple Sclerosis Market By Region, From 2016-2021 ( USD Million )
  11. Europe Transplant Rejection/Graft Versus Host Disease Market By Region, From 2016-2021 ( USD Million )
  12. Europe Other Applications Market By Region, From 2016-2021 ( USD Million )
  13. Europe Autoimmune Monoclonal Antibodies Market By End User, From 2016-2021 ( USD Million )
  14. Europe Hospitals/Clinics Market By Region, From 2016-2021 ( USD Million )
  15. Europe Research Institute Market By Region, From 2016-2021 ( USD Million )
  16. Europe Diagnostic Laboratories Market By Region, From 2016-2021 ( USD Million )
  17. U.K. Autoimmune Monoclonal Antibodies Market By Source, From 2016-2021 ( USD Million )
  18. U.K. Autoimmune Monoclonal Antibodies Market By Application, From 2016-2021 ( USD Million )
  19. U.K. Autoimmune Monoclonal Antibodies Market By End User, From 2016-2021 ( USD Million )
  20. Germany Autoimmune Monoclonal Antibodies Market By Source, From 2016-2021 ( USD Million )
  21. Germany Autoimmune Monoclonal Antibodies Market By Application, From 2016-2021 ( USD Million )
  22. Germany Autoimmune Monoclonal Antibodies Market By End User, From 2016-2021 ( USD Million )
  23. France Autoimmune Monoclonal Antibodies Market By Source, From 2016-2021 ( USD Million )
  24. France Autoimmune Monoclonal Antibodies Market By Application, From 2016-2021 ( USD Million )
  25. France Autoimmune Monoclonal Antibodies Market By End User, From 2016-2021 ( USD Million )
  26. Italy Autoimmune Monoclonal Antibodies Market By Source, From 2016-2021 ( USD Million )
  27. Italy Autoimmune Monoclonal Antibodies Market By Application, From 2016-2021 ( USD Million )
  28. Italy Autoimmune Monoclonal Antibodies Market By End User, From 2016-2021 ( USD Million )
  29. Spain Autoimmune Monoclonal Antibodies Market By Source, From 2016-2021 ( USD Million )
  30. Spain Autoimmune Monoclonal Antibodies Market By Application, From 2016-2021 ( USD Million )
  31. Spain Autoimmune Monoclonal Antibodies Market By End User, From 2016-2021 ( USD Million )

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
502, kakatiya's empire,
Jubilee Gardens,
Hyderabad, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2017 Market Data Forecast
All Rights Reserved.